JP2008542242A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008542242A5 JP2008542242A5 JP2008512845A JP2008512845A JP2008542242A5 JP 2008542242 A5 JP2008542242 A5 JP 2008542242A5 JP 2008512845 A JP2008512845 A JP 2008512845A JP 2008512845 A JP2008512845 A JP 2008512845A JP 2008542242 A5 JP2008542242 A5 JP 2008542242A5
- Authority
- JP
- Japan
- Prior art keywords
- pyridin
- cyano
- thieno
- tetrahydro
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 2,2-difluoro-1,3-benzodioxolyl Chemical group 0.000 claims 40
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 25
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 22
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 20
- 229910052801 chlorine Inorganic materials 0.000 claims 20
- 239000000460 chlorine Substances 0.000 claims 20
- 125000004076 pyridyl group Chemical group 0.000 claims 17
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 14
- 229910052731 fluorine Inorganic materials 0.000 claims 14
- 239000011737 fluorine Substances 0.000 claims 14
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 13
- 125000004432 carbon atom Chemical group C* 0.000 claims 13
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- 229910052799 carbon Inorganic materials 0.000 claims 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 9
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims 9
- 229910052757 nitrogen Inorganic materials 0.000 claims 9
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 125000001424 substituent group Chemical group 0.000 claims 7
- 125000004122 cyclic group Chemical group 0.000 claims 6
- 125000002541 furyl group Chemical group 0.000 claims 6
- 125000002950 monocyclic group Chemical group 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- 125000001544 thienyl group Chemical group 0.000 claims 6
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 239000002246 antineoplastic agent Substances 0.000 claims 5
- 230000003796 beauty Effects 0.000 claims 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 208000017604 Hodgkin disease Diseases 0.000 claims 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 210000003734 kidney Anatomy 0.000 claims 4
- 230000009826 neoplastic cell growth Effects 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 239000001301 oxygen Substances 0.000 claims 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 4
- 239000011593 sulfur Substances 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- ZYLKMRMEIHZITI-UHFFFAOYSA-N 2-(6-acetyl-3-cyano-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl)-3-phenylpropanamide Chemical compound C1N(C(=O)C)CCC(C=2C#N)=C1SC=2C(C(N)=O)CC1=CC=CC=C1 ZYLKMRMEIHZITI-UHFFFAOYSA-N 0.000 claims 3
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 3
- 206010038389 Renal cancer Diseases 0.000 claims 3
- 239000000556 agonist Substances 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 201000010982 kidney cancer Diseases 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 3
- 125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 claims 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 3
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 claims 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 2
- 206010023825 Laryngeal cancer Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010027406 Mesothelioma Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 201000000582 Retinoblastoma Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 206010042971 T-cell lymphoma Diseases 0.000 claims 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 2
- 229940124613 TLR 7/8 agonist Drugs 0.000 claims 2
- 208000008383 Wilms tumor Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 230000000973 chemotherapeutic effect Effects 0.000 claims 2
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 claims 2
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 210000003372 endocrine gland Anatomy 0.000 claims 2
- 229960001433 erlotinib Drugs 0.000 claims 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 2
- 210000003238 esophagus Anatomy 0.000 claims 2
- 229960002584 gefitinib Drugs 0.000 claims 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 2
- 210000004602 germ cell Anatomy 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 210000003128 head Anatomy 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 201000006866 hypopharynx cancer Diseases 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims 2
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 230000036210 malignancy Effects 0.000 claims 2
- 208000026037 malignant tumor of neck Diseases 0.000 claims 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 210000003739 neck Anatomy 0.000 claims 2
- 230000001613 neoplastic effect Effects 0.000 claims 2
- 201000008026 nephroblastoma Diseases 0.000 claims 2
- 229960000435 oblimersen Drugs 0.000 claims 2
- MIMNFCVQODTQDP-NDLVEFNKSA-N oblimersen Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(S)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 MIMNFCVQODTQDP-NDLVEFNKSA-N 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 210000000496 pancreas Anatomy 0.000 claims 2
- 210000001428 peripheral nervous system Anatomy 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 210000004180 plasmocyte Anatomy 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 2
- 229940080818 propionamide Drugs 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 210000000664 rectum Anatomy 0.000 claims 2
- 229930002330 retinoic acid Natural products 0.000 claims 2
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 210000003491 skin Anatomy 0.000 claims 2
- 210000000813 small intestine Anatomy 0.000 claims 2
- 210000004872 soft tissue Anatomy 0.000 claims 2
- 229960003787 sorafenib Drugs 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims 2
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 claims 2
- 210000001550 testis Anatomy 0.000 claims 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims 2
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 claims 2
- 210000003932 urinary bladder Anatomy 0.000 claims 2
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 claims 2
- 229960000604 valproic acid Drugs 0.000 claims 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- ZGNLFUXWZJGETL-YUSKDDKASA-N (Z)-[(2S)-2-amino-2-carboxyethyl]-hydroxyimino-oxidoazanium Chemical compound N[C@@H](C\[N+]([O-])=N\O)C(O)=O ZGNLFUXWZJGETL-YUSKDDKASA-N 0.000 claims 1
- BWDQBBCUWLSASG-MDZDMXLPSA-N (e)-n-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1h-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide Chemical compound C=1NC2=CC=CC=C2C=1CCN(CCO)CC1=CC=C(\C=C\C(=O)NO)C=C1 BWDQBBCUWLSASG-MDZDMXLPSA-N 0.000 claims 1
- NVKGVBZZSJFQLM-UHFFFAOYSA-N 1-(2-chloroethyl)-1-nitrosourea Chemical compound NC(=O)N(N=O)CCCl NVKGVBZZSJFQLM-UHFFFAOYSA-N 0.000 claims 1
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical class O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 claims 1
- ZFKYCRVGESMZKS-UHFFFAOYSA-N 2-amino-6-(2-pyridin-4-ylacetyl)-5,7-dihydro-4H-thieno[2,3-c]pyridine-3-carbonitrile Chemical compound C1CC=2C(C#N)=C(N)SC=2CN1C(=O)CC1=CC=NC=C1 ZFKYCRVGESMZKS-UHFFFAOYSA-N 0.000 claims 1
- RVSRKPSRXHQSNI-UHFFFAOYSA-N 2-amino-6-(3-imidazol-1-ylpropanoyl)-5,7-dihydro-4H-thieno[2,3-c]pyridine-3-carbonitrile Chemical compound C1CC=2C(C#N)=C(N)SC=2CN1C(=O)CCN1C=CN=C1 RVSRKPSRXHQSNI-UHFFFAOYSA-N 0.000 claims 1
- ZZVMTTYYCJKWEP-UHFFFAOYSA-N 2-amino-6-(3-pyridin-3-ylpropanoyl)-5,7-dihydro-4H-thieno[2,3-c]pyridine-3-carbonitrile Chemical compound C1CC=2C(C#N)=C(N)SC=2CN1C(=O)CCC1=CC=CN=C1 ZZVMTTYYCJKWEP-UHFFFAOYSA-N 0.000 claims 1
- AHDDRJBFJBDEPW-UHFFFAOYSA-N 2-phenylcyclopropane-1-carboxylic acid Chemical compound OC(=O)C1CC1C1=CC=CC=C1 AHDDRJBFJBDEPW-UHFFFAOYSA-N 0.000 claims 1
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 claims 1
- TZYVRXZQAWPIAB-FCLHUMLKSA-N 5-amino-3-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4h-[1,3]thiazolo[4,5-d]pyrimidine-2,7-dione Chemical compound O=C1SC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O TZYVRXZQAWPIAB-FCLHUMLKSA-N 0.000 claims 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 1
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 108010006654 Bleomycin Proteins 0.000 claims 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000009058 Death Domain Receptors Human genes 0.000 claims 1
- 108010049207 Death Domain Receptors Proteins 0.000 claims 1
- 108010002156 Depsipeptides Proteins 0.000 claims 1
- 102000015212 Fas Ligand Protein Human genes 0.000 claims 1
- 108010039471 Fas Ligand Protein Proteins 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 claims 1
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 108010078049 Interferon alpha-2 Proteins 0.000 claims 1
- 102100039350 Interferon alpha-7 Human genes 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- MLFKVJCWGUZWNV-UHFFFAOYSA-N L-alanosine Natural products OC(=O)C(N)CN(O)N=O MLFKVJCWGUZWNV-UHFFFAOYSA-N 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 229940121849 Mitotic inhibitor Drugs 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 229940079156 Proteasome inhibitor Drugs 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000032383 Soft tissue cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 229940123237 Taxane Drugs 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims 1
- 102000002689 Toll-like receptor Human genes 0.000 claims 1
- 108020000411 Toll-like receptor Proteins 0.000 claims 1
- 208000023915 Ureteral Neoplasms Diseases 0.000 claims 1
- 206010046392 Ureteric cancer Diseases 0.000 claims 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 229940122803 Vinca alkaloid Drugs 0.000 claims 1
- DYGKALZZBMZIGH-UHFFFAOYSA-N [2-[3-cyano-2-(3-phenylpropanoylamino)-5,7-dihydro-4h-thieno[2,3-c]pyridin-6-yl]-2-oxoethyl] acetate Chemical compound C1N(C(=O)COC(=O)C)CCC(C=2C#N)=C1SC=2NC(=O)CCC1=CC=CC=C1 DYGKALZZBMZIGH-UHFFFAOYSA-N 0.000 claims 1
- 229950005033 alanosine Drugs 0.000 claims 1
- 229940060265 aldara Drugs 0.000 claims 1
- 230000002152 alkylating effect Effects 0.000 claims 1
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 1
- 230000002280 anti-androgenic effect Effects 0.000 claims 1
- 230000001772 anti-angiogenic effect Effects 0.000 claims 1
- 229940046836 anti-estrogen Drugs 0.000 claims 1
- 230000001833 anti-estrogenic effect Effects 0.000 claims 1
- 239000000051 antiandrogen Substances 0.000 claims 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 239000003886 aromatase inhibitor Substances 0.000 claims 1
- 229940046844 aromatase inhibitors Drugs 0.000 claims 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 229960002756 azacitidine Drugs 0.000 claims 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 1
- 229960003094 belinostat Drugs 0.000 claims 1
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 claims 1
- 125000004533 benzofuran-5-yl group Chemical group O1C=CC2=C1C=CC(=C2)* 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 229960001561 bleomycin Drugs 0.000 claims 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 1
- 229940127093 camptothecin Drugs 0.000 claims 1
- 229960004117 capecitabine Drugs 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- WDOGQTQEKVLZIJ-WAYWQWQTSA-N combretastatin a-4 phosphate Chemical compound C1=C(OP(O)(O)=O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 WDOGQTQEKVLZIJ-WAYWQWQTSA-N 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229960000684 cytarabine Drugs 0.000 claims 1
- 229960003603 decitabine Drugs 0.000 claims 1
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 claims 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000004696 endometrium Anatomy 0.000 claims 1
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 claims 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 claims 1
- 229930013356 epothilone Natural products 0.000 claims 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 claims 1
- 239000000328 estrogen antagonist Substances 0.000 claims 1
- 229960000390 fludarabine Drugs 0.000 claims 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- 239000004052 folic acid antagonist Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims 1
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 claims 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 1
- 230000003054 hormonal effect Effects 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims 1
- 229960001101 ifosfamide Drugs 0.000 claims 1
- 229960002411 imatinib Drugs 0.000 claims 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 1
- 229960002751 imiquimod Drugs 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 230000006882 induction of apoptosis Effects 0.000 claims 1
- 229960003130 interferon gamma Drugs 0.000 claims 1
- 229940047124 interferons Drugs 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 229950003954 isatoribine Drugs 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 210000000867 larynx Anatomy 0.000 claims 1
- 201000004962 larynx cancer Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 1
- 229960001924 melphalan Drugs 0.000 claims 1
- 229960001428 mercaptopurine Drugs 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 1
- 239000003697 methyltransferase inhibitor Substances 0.000 claims 1
- 230000000394 mitotic effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- MGGUTZGJDZLFMA-UHFFFAOYSA-N n-(6-butanoyl-3-cyano-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl)-3-(furan-2-yl)propanamide Chemical compound C1N(C(=O)CCC)CCC(C=2C#N)=C1SC=2NC(=O)CCC1=CC=CO1 MGGUTZGJDZLFMA-UHFFFAOYSA-N 0.000 claims 1
- KSXQQRANKSRZPL-UHFFFAOYSA-N n-(6-butanoyl-3-cyano-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl)-3-phenylbutanamide Chemical compound C1N(C(=O)CCC)CCC(C=2C#N)=C1SC=2NC(=O)CC(C)C1=CC=CC=C1 KSXQQRANKSRZPL-UHFFFAOYSA-N 0.000 claims 1
- POTFHQIEFBHKPE-UHFFFAOYSA-N n-(6-butanoyl-3-cyano-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl)-3-phenylpropanamide Chemical compound C1N(C(=O)CCC)CCC(C=2C#N)=C1SC=2NC(=O)CCC1=CC=CC=C1 POTFHQIEFBHKPE-UHFFFAOYSA-N 0.000 claims 1
- XFLCEDQNMYYLIN-UHFFFAOYSA-N n-[3-cyano-6-(2-hydroxyacetyl)-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-(furan-2-yl)propanamide Chemical compound C1N(C(=O)CO)CCC(C=2C#N)=C1SC=2NC(=O)CCC1=CC=CO1 XFLCEDQNMYYLIN-UHFFFAOYSA-N 0.000 claims 1
- FAUQTKUFFLVGRH-UHFFFAOYSA-N n-[3-cyano-6-(2-hydroxyacetyl)-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-cyclohexylpropanamide Chemical compound C1N(C(=O)CO)CCC(C=2C#N)=C1SC=2NC(=O)CCC1CCCCC1 FAUQTKUFFLVGRH-UHFFFAOYSA-N 0.000 claims 1
- KJPKDRMKZGWMRX-UHFFFAOYSA-N n-[3-cyano-6-(2-hydroxyacetyl)-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-phenylbutanamide Chemical compound S1C=2CN(C(=O)CO)CCC=2C(C#N)=C1NC(=O)CC(C)C1=CC=CC=C1 KJPKDRMKZGWMRX-UHFFFAOYSA-N 0.000 claims 1
- CWHMUSRBIGRSSU-UHFFFAOYSA-N n-[3-cyano-6-(2-hydroxyacetyl)-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-phenylpropanamide Chemical compound C1N(C(=O)CO)CCC(C=2C#N)=C1SC=2NC(=O)CCC1=CC=CC=C1 CWHMUSRBIGRSSU-UHFFFAOYSA-N 0.000 claims 1
- LEEIFYGOQQMDEH-UHFFFAOYSA-N n-[3-cyano-6-(2-hydroxyacetyl)-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-pyridin-2-ylpropanamide Chemical compound C1N(C(=O)CO)CCC(C=2C#N)=C1SC=2NC(=O)CCC1=CC=CC=N1 LEEIFYGOQQMDEH-UHFFFAOYSA-N 0.000 claims 1
- FSFPVZSDGOXOCT-UHFFFAOYSA-N n-[3-cyano-6-(2-hydroxyacetyl)-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-pyridin-3-ylpropanamide Chemical compound C1N(C(=O)CO)CCC(C=2C#N)=C1SC=2NC(=O)CCC1=CC=CN=C1 FSFPVZSDGOXOCT-UHFFFAOYSA-N 0.000 claims 1
- HVDJCWQZUMVCNN-UHFFFAOYSA-N n-[3-cyano-6-(2-imidazol-1-ylacetyl)-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-(furan-2-yl)propanamide Chemical compound S1C=2CN(C(=O)CN3C=NC=C3)CCC=2C(C#N)=C1NC(=O)CCC1=CC=CO1 HVDJCWQZUMVCNN-UHFFFAOYSA-N 0.000 claims 1
- SXLVPBKWOFGQBF-UHFFFAOYSA-N n-[3-cyano-6-(2-imidazol-1-ylacetyl)-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-cyclohexylpropanamide Chemical compound S1C=2CN(C(=O)CN3C=NC=C3)CCC=2C(C#N)=C1NC(=O)CCC1CCCCC1 SXLVPBKWOFGQBF-UHFFFAOYSA-N 0.000 claims 1
- NDKACLHVZDYZRM-UHFFFAOYSA-N n-[3-cyano-6-(2-imidazol-1-ylacetyl)-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-phenylbutanamide Chemical compound C=1C=CC=CC=1C(C)CC(=O)NC(=C(C=1CC2)C#N)SC=1CN2C(=O)CN1C=CN=C1 NDKACLHVZDYZRM-UHFFFAOYSA-N 0.000 claims 1
- JMWDBMPDXBDGGQ-UHFFFAOYSA-N n-[3-cyano-6-(2-imidazol-1-ylacetyl)-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-phenylpropanamide Chemical compound S1C=2CN(C(=O)CN3C=NC=C3)CCC=2C(C#N)=C1NC(=O)CCC1=CC=CC=C1 JMWDBMPDXBDGGQ-UHFFFAOYSA-N 0.000 claims 1
- GNNNQRVSPUSECJ-UHFFFAOYSA-N n-[3-cyano-6-(2-methoxyacetyl)-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-(furan-2-yl)propanamide Chemical compound C1N(C(=O)COC)CCC(C=2C#N)=C1SC=2NC(=O)CCC1=CC=CO1 GNNNQRVSPUSECJ-UHFFFAOYSA-N 0.000 claims 1
- LUQJTXYIPYYSNL-UHFFFAOYSA-N n-[3-cyano-6-(2-methoxyacetyl)-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-phenylpropanamide Chemical compound C1N(C(=O)COC)CCC(C=2C#N)=C1SC=2NC(=O)CCC1=CC=CC=C1 LUQJTXYIPYYSNL-UHFFFAOYSA-N 0.000 claims 1
- QFLJVEOWTJLVBF-UHFFFAOYSA-N n-[3-cyano-6-(2-pyridin-2-ylacetyl)-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-(furan-2-yl)propanamide Chemical compound S1C=2CN(C(=O)CC=3N=CC=CC=3)CCC=2C(C#N)=C1NC(=O)CCC1=CC=CO1 QFLJVEOWTJLVBF-UHFFFAOYSA-N 0.000 claims 1
- CEVJEJBQTXYDOM-UHFFFAOYSA-N n-[3-cyano-6-(2-pyridin-2-ylacetyl)-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-cyclohexylpropanamide Chemical compound S1C=2CN(C(=O)CC=3N=CC=CC=3)CCC=2C(C#N)=C1NC(=O)CCC1CCCCC1 CEVJEJBQTXYDOM-UHFFFAOYSA-N 0.000 claims 1
- XRAUUGFQFBALJV-UHFFFAOYSA-N n-[3-cyano-6-(2-pyridin-2-ylacetyl)-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-phenylbutanamide Chemical compound C=1C=CC=CC=1C(C)CC(=O)NC(=C(C=1CC2)C#N)SC=1CN2C(=O)CC1=CC=CC=N1 XRAUUGFQFBALJV-UHFFFAOYSA-N 0.000 claims 1
- HTVYUQKTMWFMDV-UHFFFAOYSA-N n-[3-cyano-6-(2-pyridin-3-ylacetyl)-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-(furan-2-yl)propanamide Chemical compound S1C=2CN(C(=O)CC=3C=NC=CC=3)CCC=2C(C#N)=C1NC(=O)CCC1=CC=CO1 HTVYUQKTMWFMDV-UHFFFAOYSA-N 0.000 claims 1
- RDKLYCOFBPRQQH-UHFFFAOYSA-N n-[3-cyano-6-(2-pyridin-3-ylacetyl)-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-cyclohexylpropanamide Chemical compound S1C=2CN(C(=O)CC=3C=NC=CC=3)CCC=2C(C#N)=C1NC(=O)CCC1CCCCC1 RDKLYCOFBPRQQH-UHFFFAOYSA-N 0.000 claims 1
- LXHXMTKTMVBJIS-UHFFFAOYSA-N n-[3-cyano-6-(2-pyridin-3-ylacetyl)-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-phenylbutanamide Chemical compound C=1C=CC=CC=1C(C)CC(=O)NC(=C(C=1CC2)C#N)SC=1CN2C(=O)CC1=CC=CN=C1 LXHXMTKTMVBJIS-UHFFFAOYSA-N 0.000 claims 1
- YKOGEHLBCMZVLU-UHFFFAOYSA-N n-[3-cyano-6-(2-pyridin-4-ylacetyl)-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-2-phenylcyclopropane-1-carboxamide Chemical compound C1CC(C(=C(NC(=O)C2C(C2)C=2C=CC=CC=2)S2)C#N)=C2CN1C(=O)CC1=CC=NC=C1 YKOGEHLBCMZVLU-UHFFFAOYSA-N 0.000 claims 1
- FTOXQBDKYHOWMR-UHFFFAOYSA-N n-[3-cyano-6-(2-pyridin-4-ylacetyl)-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-(furan-2-yl)propanamide Chemical compound S1C=2CN(C(=O)CC=3C=CN=CC=3)CCC=2C(C#N)=C1NC(=O)CCC1=CC=CO1 FTOXQBDKYHOWMR-UHFFFAOYSA-N 0.000 claims 1
- ISJSEIDXELCWNV-UHFFFAOYSA-N n-[3-cyano-6-(2-pyridin-4-ylacetyl)-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-cyclohexylpropanamide Chemical compound S1C=2CN(C(=O)CC=3C=CN=CC=3)CCC=2C(C#N)=C1NC(=O)CCC1CCCCC1 ISJSEIDXELCWNV-UHFFFAOYSA-N 0.000 claims 1
- CWHRGXRLRVTVMU-UHFFFAOYSA-N n-[3-cyano-6-(2-pyridin-4-ylacetyl)-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-phenylbutanamide Chemical compound C=1C=CC=CC=1C(C)CC(=O)NC(=C(C=1CC2)C#N)SC=1CN2C(=O)CC1=CC=NC=C1 CWHRGXRLRVTVMU-UHFFFAOYSA-N 0.000 claims 1
- VHQFJCFYJZTKJZ-UHFFFAOYSA-N n-[3-cyano-6-(2-pyridin-4-ylacetyl)-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-phenylpropanamide Chemical compound S1C=2CN(C(=O)CC=3C=CN=CC=3)CCC=2C(C#N)=C1NC(=O)CCC1=CC=CC=C1 VHQFJCFYJZTKJZ-UHFFFAOYSA-N 0.000 claims 1
- XRDQEWKKQRGPMU-UHFFFAOYSA-N n-[3-cyano-6-(3-hydroxypropanoyl)-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-2-phenylcyclopropane-1-carboxamide Chemical compound C1N(C(=O)CCO)CCC(C=2C#N)=C1SC=2NC(=O)C1CC1C1=CC=CC=C1 XRDQEWKKQRGPMU-UHFFFAOYSA-N 0.000 claims 1
- PWUAWIGBQNMRMK-UHFFFAOYSA-N n-[3-cyano-6-(3-hydroxypropanoyl)-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-(furan-2-yl)propanamide Chemical compound C1N(C(=O)CCO)CCC(C=2C#N)=C1SC=2NC(=O)CCC1=CC=CO1 PWUAWIGBQNMRMK-UHFFFAOYSA-N 0.000 claims 1
- YXLXUVSMBPLECJ-UHFFFAOYSA-N n-[3-cyano-6-(3-hydroxypropanoyl)-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-cyclohexylpropanamide Chemical compound C1N(C(=O)CCO)CCC(C=2C#N)=C1SC=2NC(=O)CCC1CCCCC1 YXLXUVSMBPLECJ-UHFFFAOYSA-N 0.000 claims 1
- VEZWRANBGONAPR-UHFFFAOYSA-N n-[3-cyano-6-(3-hydroxypropanoyl)-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-phenylbutanamide Chemical compound S1C=2CN(C(=O)CCO)CCC=2C(C#N)=C1NC(=O)CC(C)C1=CC=CC=C1 VEZWRANBGONAPR-UHFFFAOYSA-N 0.000 claims 1
- ALRHDQWPSGCEKC-UHFFFAOYSA-N n-[3-cyano-6-(3-hydroxypropanoyl)-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-phenylpropanamide Chemical compound C1N(C(=O)CCO)CCC(C=2C#N)=C1SC=2NC(=O)CCC1=CC=CC=C1 ALRHDQWPSGCEKC-UHFFFAOYSA-N 0.000 claims 1
- MDOLPVCYUJERQW-UHFFFAOYSA-N n-[3-cyano-6-(3-hydroxypropanoyl)-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-pyridin-2-ylpropanamide Chemical compound C1N(C(=O)CCO)CCC(C=2C#N)=C1SC=2NC(=O)CCC1=CC=CC=N1 MDOLPVCYUJERQW-UHFFFAOYSA-N 0.000 claims 1
- NXMQIIUYTXEZPV-UHFFFAOYSA-N n-[3-cyano-6-(3-hydroxypropanoyl)-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-pyridin-3-ylpropanamide Chemical compound C1N(C(=O)CCO)CCC(C=2C#N)=C1SC=2NC(=O)CCC1=CC=CN=C1 NXMQIIUYTXEZPV-UHFFFAOYSA-N 0.000 claims 1
- YRPLFJYIEHHVTG-UHFFFAOYSA-N n-[3-cyano-6-(3-imidazol-1-ylpropanoyl)-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-(furan-2-yl)propanamide Chemical compound S1C=2CN(C(=O)CCN3C=NC=C3)CCC=2C(C#N)=C1NC(=O)CCC1=CC=CO1 YRPLFJYIEHHVTG-UHFFFAOYSA-N 0.000 claims 1
- DBCGEHYLLPCZDL-UHFFFAOYSA-N n-[3-cyano-6-(3-imidazol-1-ylpropanoyl)-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-cyclohexylpropanamide Chemical compound S1C=2CN(C(=O)CCN3C=NC=C3)CCC=2C(C#N)=C1NC(=O)CCC1CCCCC1 DBCGEHYLLPCZDL-UHFFFAOYSA-N 0.000 claims 1
- CPLNAKKFDSIEIX-UHFFFAOYSA-N n-[3-cyano-6-(3-imidazol-1-ylpropanoyl)-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-phenylbutanamide Chemical compound C=1C=CC=CC=1C(C)CC(=O)NC(=C(C=1CC2)C#N)SC=1CN2C(=O)CCN1C=CN=C1 CPLNAKKFDSIEIX-UHFFFAOYSA-N 0.000 claims 1
- VVJNSMLNUPOAKO-UHFFFAOYSA-N n-[3-cyano-6-(3-imidazol-1-ylpropanoyl)-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-phenylpropanamide Chemical compound S1C=2CN(C(=O)CCN3C=NC=C3)CCC=2C(C#N)=C1NC(=O)CCC1=CC=CC=C1 VVJNSMLNUPOAKO-UHFFFAOYSA-N 0.000 claims 1
- KBBVQGLMLCDJEC-UHFFFAOYSA-N n-[3-cyano-6-(3-morpholin-4-ylpropanoyl)-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-phenylpropanamide Chemical compound S1C=2CN(C(=O)CCN3CCOCC3)CCC=2C(C#N)=C1NC(=O)CCC1=CC=CC=C1 KBBVQGLMLCDJEC-UHFFFAOYSA-N 0.000 claims 1
- HWWCLRRYTPUKBI-UHFFFAOYSA-N n-[3-cyano-6-(3-pyridin-2-ylpropanoyl)-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-(furan-2-yl)propanamide Chemical compound S1C=2CN(C(=O)CCC=3N=CC=CC=3)CCC=2C(C#N)=C1NC(=O)CCC1=CC=CO1 HWWCLRRYTPUKBI-UHFFFAOYSA-N 0.000 claims 1
- VMYVOABNZJBWAV-UHFFFAOYSA-N n-[3-cyano-6-(3-pyridin-2-ylpropanoyl)-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-cyclohexylpropanamide Chemical compound S1C=2CN(C(=O)CCC=3N=CC=CC=3)CCC=2C(C#N)=C1NC(=O)CCC1CCCCC1 VMYVOABNZJBWAV-UHFFFAOYSA-N 0.000 claims 1
- GXVZBAMBKWFKLU-UHFFFAOYSA-N n-[3-cyano-6-(3-pyridin-2-ylpropanoyl)-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-phenylbutanamide Chemical compound C=1C=CC=CC=1C(C)CC(=O)NC(=C(C=1CC2)C#N)SC=1CN2C(=O)CCC1=CC=CC=N1 GXVZBAMBKWFKLU-UHFFFAOYSA-N 0.000 claims 1
- XLZOEJDLSKLHAH-UHFFFAOYSA-N n-[3-cyano-6-(3-pyridin-2-ylpropanoyl)-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-phenylpropanamide Chemical compound S1C=2CN(C(=O)CCC=3N=CC=CC=3)CCC=2C(C#N)=C1NC(=O)CCC1=CC=CC=C1 XLZOEJDLSKLHAH-UHFFFAOYSA-N 0.000 claims 1
- WVEDGEBWPLIERU-UHFFFAOYSA-N n-[3-cyano-6-(3-pyridin-3-ylpropanoyl)-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-(furan-2-yl)propanamide Chemical compound S1C=2CN(C(=O)CCC=3C=NC=CC=3)CCC=2C(C#N)=C1NC(=O)CCC1=CC=CO1 WVEDGEBWPLIERU-UHFFFAOYSA-N 0.000 claims 1
- IVSAMTUKOSPFTC-UHFFFAOYSA-N n-[3-cyano-6-(3-pyridin-3-ylpropanoyl)-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-cyclohexylpropanamide Chemical compound S1C=2CN(C(=O)CCC=3C=NC=CC=3)CCC=2C(C#N)=C1NC(=O)CCC1CCCCC1 IVSAMTUKOSPFTC-UHFFFAOYSA-N 0.000 claims 1
- KKNPTXNPQAMXTQ-UHFFFAOYSA-N n-[3-cyano-6-(3-pyridin-3-ylpropanoyl)-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-phenylbutanamide Chemical compound C=1C=CC=CC=1C(C)CC(=O)NC(=C(C=1CC2)C#N)SC=1CN2C(=O)CCC1=CC=CN=C1 KKNPTXNPQAMXTQ-UHFFFAOYSA-N 0.000 claims 1
- QXOQDYYFHSJWSV-UHFFFAOYSA-N n-[3-cyano-6-(3-pyridin-3-ylpropanoyl)-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-phenylpropanamide Chemical compound S1C=2CN(C(=O)CCC=3C=NC=CC=3)CCC=2C(C#N)=C1NC(=O)CCC1=CC=CC=C1 QXOQDYYFHSJWSV-UHFFFAOYSA-N 0.000 claims 1
- NKGLHHZNQWIJAQ-UHFFFAOYSA-N n-[3-cyano-6-(3-pyridin-4-ylpropanoyl)-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-(furan-2-yl)propanamide Chemical compound S1C=2CN(C(=O)CCC=3C=CN=CC=3)CCC=2C(C#N)=C1NC(=O)CCC1=CC=CO1 NKGLHHZNQWIJAQ-UHFFFAOYSA-N 0.000 claims 1
- QNNBNUUYJLPYAQ-UHFFFAOYSA-N n-[3-cyano-6-(3-pyridin-4-ylpropanoyl)-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-cyclohexylpropanamide Chemical compound S1C=2CN(C(=O)CCC=3C=CN=CC=3)CCC=2C(C#N)=C1NC(=O)CCC1CCCCC1 QNNBNUUYJLPYAQ-UHFFFAOYSA-N 0.000 claims 1
- QBARGTRXDPSJEP-UHFFFAOYSA-N n-[3-cyano-6-(3-pyridin-4-ylpropanoyl)-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-phenylbutanamide Chemical compound C=1C=CC=CC=1C(C)CC(=O)NC(=C(C=1CC2)C#N)SC=1CN2C(=O)CCC1=CC=NC=C1 QBARGTRXDPSJEP-UHFFFAOYSA-N 0.000 claims 1
- INLWDAOBQKKDMT-UHFFFAOYSA-N n-[3-cyano-6-(3-pyridin-4-ylpropanoyl)-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-phenylpropanamide Chemical compound S1C=2CN(C(=O)CCC=3C=CN=CC=3)CCC=2C(C#N)=C1NC(=O)CCC1=CC=CC=C1 INLWDAOBQKKDMT-UHFFFAOYSA-N 0.000 claims 1
- SJXRIUOYYDQKBU-UHFFFAOYSA-N n-[3-cyano-6-[2-(2,4-dimethylimidazol-1-yl)acetyl]-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-phenylbutanamide Chemical compound C=1C=CC=CC=1C(C)CC(=O)NC(=C(C=1CC2)C#N)SC=1CN2C(=O)CN1C=C(C)N=C1C SJXRIUOYYDQKBU-UHFFFAOYSA-N 0.000 claims 1
- KDASPCTYOCDCQR-UHFFFAOYSA-N n-[3-cyano-6-[2-(2,4-dimethylimidazol-1-yl)acetyl]-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-phenylpropanamide Chemical compound CC1=NC(C)=CN1CC(=O)N1CC(SC(NC(=O)CCC=2C=CC=CC=2)=C2C#N)=C2CC1 KDASPCTYOCDCQR-UHFFFAOYSA-N 0.000 claims 1
- VQBXXRDTKCDWQC-UHFFFAOYSA-N n-[3-cyano-6-[2-(2-methoxyethoxy)acetyl]-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-(furan-2-yl)propanamide Chemical compound C1N(C(=O)COCCOC)CCC(C=2C#N)=C1SC=2NC(=O)CCC1=CC=CO1 VQBXXRDTKCDWQC-UHFFFAOYSA-N 0.000 claims 1
- OCSGUJIIYJOENJ-UHFFFAOYSA-N n-[3-cyano-6-[2-(2-methylimidazol-1-yl)acetyl]-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-phenylbutanamide Chemical compound C=1C=CC=CC=1C(C)CC(=O)NC(=C(C=1CC2)C#N)SC=1CN2C(=O)CN1C=CN=C1C OCSGUJIIYJOENJ-UHFFFAOYSA-N 0.000 claims 1
- JILCFODLOPNJBT-UHFFFAOYSA-N n-[3-cyano-6-[2-(2-methylimidazol-1-yl)acetyl]-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-phenylpropanamide Chemical compound CC1=NC=CN1CC(=O)N1CC(SC(NC(=O)CCC=2C=CC=CC=2)=C2C#N)=C2CC1 JILCFODLOPNJBT-UHFFFAOYSA-N 0.000 claims 1
- FPIWESVWYSWWHM-UHFFFAOYSA-N n-[3-cyano-6-[2-(4-methylimidazol-1-yl)acetyl]-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-phenylbutanamide Chemical compound C=1C=CC=CC=1C(C)CC(=O)NC(=C(C=1CC2)C#N)SC=1CN2C(=O)CN1C=NC(C)=C1 FPIWESVWYSWWHM-UHFFFAOYSA-N 0.000 claims 1
- IHBHXMOLABDYGX-UHFFFAOYSA-N n-[3-cyano-6-[2-(4-methylimidazol-1-yl)acetyl]-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-phenylpropanamide Chemical compound C1=NC(C)=CN1CC(=O)N1CC(SC(NC(=O)CCC=2C=CC=CC=2)=C2C#N)=C2CC1 IHBHXMOLABDYGX-UHFFFAOYSA-N 0.000 claims 1
- DDBGCJUWHQCZIW-UHFFFAOYSA-N n-[3-cyano-6-[3-(1-methylimidazol-2-yl)propanoyl]-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-2-phenylcyclopropane-1-carboxamide Chemical compound CN1C=CN=C1CCC(=O)N1CC(SC(NC(=O)C2C(C2)C=2C=CC=CC=2)=C2C#N)=C2CC1 DDBGCJUWHQCZIW-UHFFFAOYSA-N 0.000 claims 1
- ZQPCJWYHDOXKOH-UHFFFAOYSA-N n-[3-cyano-6-[3-(1-methylimidazol-2-yl)propanoyl]-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-(furan-2-yl)propanamide Chemical compound CN1C=CN=C1CCC(=O)N1CC(SC(NC(=O)CCC=2OC=CC=2)=C2C#N)=C2CC1 ZQPCJWYHDOXKOH-UHFFFAOYSA-N 0.000 claims 1
- NYBCXLVSZXDQST-UHFFFAOYSA-N n-[3-cyano-6-[3-(1-methylimidazol-2-yl)propanoyl]-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-cyclohexylpropanamide Chemical compound CN1C=CN=C1CCC(=O)N1CC(SC(NC(=O)CCC2CCCCC2)=C2C#N)=C2CC1 NYBCXLVSZXDQST-UHFFFAOYSA-N 0.000 claims 1
- MWEQUOMTDLATDU-UHFFFAOYSA-N n-[3-cyano-6-[3-(1-methylimidazol-2-yl)propanoyl]-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-phenylbutanamide Chemical compound C=1C=CC=CC=1C(C)CC(=O)NC(=C(C=1CC2)C#N)SC=1CN2C(=O)CCC1=NC=CN1C MWEQUOMTDLATDU-UHFFFAOYSA-N 0.000 claims 1
- BXTQAFVLBZVOOJ-UHFFFAOYSA-N n-[3-cyano-6-[3-(1-methylimidazol-2-yl)propanoyl]-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-phenylpropanamide Chemical compound CN1C=CN=C1CCC(=O)N1CC(SC(NC(=O)CCC=2C=CC=CC=2)=C2C#N)=C2CC1 BXTQAFVLBZVOOJ-UHFFFAOYSA-N 0.000 claims 1
- UEEZCUWDAPAMJO-UHFFFAOYSA-N n-[3-cyano-6-[3-(2,4-dimethylimidazol-1-yl)propanoyl]-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-phenylbutanamide Chemical compound C=1C=CC=CC=1C(C)CC(=O)NC(=C(C=1CC2)C#N)SC=1CN2C(=O)CCN1C=C(C)N=C1C UEEZCUWDAPAMJO-UHFFFAOYSA-N 0.000 claims 1
- ZTLPJVAQFRCUHD-UHFFFAOYSA-N n-[3-cyano-6-[3-(2,4-dimethylimidazol-1-yl)propanoyl]-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-phenylpropanamide Chemical compound CC1=NC(C)=CN1CCC(=O)N1CC(SC(NC(=O)CCC=2C=CC=CC=2)=C2C#N)=C2CC1 ZTLPJVAQFRCUHD-UHFFFAOYSA-N 0.000 claims 1
- ZBPNTRORTMJYLJ-UHFFFAOYSA-N n-[3-cyano-6-[3-(2-methylbenzimidazol-1-yl)propanoyl]-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-phenylpropanamide Chemical compound CC1=NC2=CC=CC=C2N1CCC(=O)N(C1)CCC(C=2C#N)=C1SC=2NC(=O)CCC1=CC=CC=C1 ZBPNTRORTMJYLJ-UHFFFAOYSA-N 0.000 claims 1
- MQHHBJNSKLIERZ-UHFFFAOYSA-N n-[3-cyano-6-[3-(2-methylimidazol-1-yl)propanoyl]-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-phenylbutanamide Chemical compound C=1C=CC=CC=1C(C)CC(=O)NC(=C(C=1CC2)C#N)SC=1CN2C(=O)CCN1C=CN=C1C MQHHBJNSKLIERZ-UHFFFAOYSA-N 0.000 claims 1
- WNRJUPQPIPAYTJ-UHFFFAOYSA-N n-[3-cyano-6-[3-(2-methylimidazol-1-yl)propanoyl]-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-phenylpropanamide Chemical compound CC1=NC=CN1CCC(=O)N1CC(SC(NC(=O)CCC=2C=CC=CC=2)=C2C#N)=C2CC1 WNRJUPQPIPAYTJ-UHFFFAOYSA-N 0.000 claims 1
- DJRMERNMKCNQHV-UHFFFAOYSA-N n-[3-cyano-6-[3-(4-methylimidazol-1-yl)propanoyl]-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-phenylbutanamide Chemical compound C=1C=CC=CC=1C(C)CC(=O)NC(=C(C=1CC2)C#N)SC=1CN2C(=O)CCN1C=NC(C)=C1 DJRMERNMKCNQHV-UHFFFAOYSA-N 0.000 claims 1
- ODTCACCBWDCCGH-UHFFFAOYSA-N n-[3-cyano-6-[3-(4-methylimidazol-1-yl)propanoyl]-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-phenylpropanamide Chemical compound C1=NC(C)=CN1CCC(=O)N1CC(SC(NC(=O)CCC=2C=CC=CC=2)=C2C#N)=C2CC1 ODTCACCBWDCCGH-UHFFFAOYSA-N 0.000 claims 1
- LFNALUSNPSXUDB-UHFFFAOYSA-N n-[3-cyano-6-[3-(4-methylpiperazin-1-yl)propanoyl]-5,7-dihydro-4h-thieno[2,3-c]pyridin-2-yl]-3-phenylpropanamide Chemical compound C1CN(C)CCN1CCC(=O)N1CC(SC(NC(=O)CCC=2C=CC=CC=2)=C2C#N)=C2CC1 LFNALUSNPSXUDB-UHFFFAOYSA-N 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- FPOHNWQLNRZRFC-ZHACJKMWSA-N panobinostat Chemical compound CC=1NC2=CC=CC=C2C=1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FPOHNWQLNRZRFC-ZHACJKMWSA-N 0.000 claims 1
- 229960005079 pemetrexed Drugs 0.000 claims 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 239000008024 pharmaceutical diluent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 125000005359 phenoxyalkyl group Chemical group 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 150000003057 platinum Chemical class 0.000 claims 1
- 229960001237 podophyllotoxin Drugs 0.000 claims 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 claims 1
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000003207 proteasome inhibitor Substances 0.000 claims 1
- 239000000649 purine antagonist Substances 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 239000003790 pyrimidine antagonist Substances 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 229950010550 resiquimod Drugs 0.000 claims 1
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000002314 small intestine cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 229960001796 sunitinib Drugs 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 229960001196 thiotepa Drugs 0.000 claims 1
- 229960003087 tioguanine Drugs 0.000 claims 1
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 claims 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
- 239000003744 tubulin modulator Substances 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 1
- 210000000626 ureter Anatomy 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- 210000001215 vagina Anatomy 0.000 claims 1
- 206010046885 vaginal cancer Diseases 0.000 claims 1
- 208000013139 vaginal neoplasm Diseases 0.000 claims 1
- 239000004066 vascular targeting agent Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05104499 | 2005-05-25 | ||
| EP05112150 | 2005-12-14 | ||
| PCT/EP2006/062613 WO2006125813A2 (en) | 2005-05-25 | 2006-05-24 | Tetrahydropyridothiophenes for use in the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008542242A JP2008542242A (ja) | 2008-11-27 |
| JP2008542242A5 true JP2008542242A5 (https=) | 2009-05-14 |
Family
ID=36658837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008512845A Pending JP2008542242A (ja) | 2005-05-25 | 2006-05-24 | 新規のテトラヒドロピリドチオフェン |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7714136B2 (https=) |
| EP (1) | EP1896484A2 (https=) |
| JP (1) | JP2008542242A (https=) |
| AU (1) | AU2006251167A1 (https=) |
| CA (1) | CA2609003A1 (https=) |
| WO (1) | WO2006125813A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2309765T3 (es) | 2004-05-28 | 2008-12-16 | 4Sc Ag | Tetrahidropiridotiofenos. |
| US7714134B2 (en) | 2004-06-11 | 2010-05-11 | 4Sc Ag | Compounds and use of tetrahydropyridothiophenes |
| EP1851229A1 (en) | 2005-02-09 | 2007-11-07 | Nycomed GmbH | Tetrahydropyridothiophenes for the treatment of proliferative diseases such as cancer |
| AU2006212179A1 (en) | 2005-02-11 | 2006-08-17 | 4Sc Ag | Tetrahydropyridothiophenes as antripoliferative agents for the treatment of cancer |
| US7714136B2 (en) | 2005-05-25 | 2010-05-11 | 4Sc Ag | Tetrahydropyridothiophenes |
| US7763728B2 (en) | 2005-05-25 | 2010-07-27 | 4Sc Ag | Tetrahydropyridothiophenes |
| CA2648642A1 (en) * | 2006-04-11 | 2007-10-25 | Merck & Co., Inc. | Niacin receptor agonists, compositions containing such compounds and methods of treatment |
| AR077405A1 (es) | 2009-07-10 | 2011-08-24 | Sanofi Aventis | Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer |
| FR2949467B1 (fr) | 2009-09-03 | 2011-11-25 | Sanofi Aventis | Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation |
| BR112020025696A2 (pt) | 2018-06-19 | 2021-03-16 | Novartis Ag | Derivados de tetra-hidrotienopiridina n-substituída e usos dos mesmos |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE272078C (https=) | ||||
| SE338693B (https=) * | 1965-02-10 | 1971-09-13 | Rotax Ltd | |
| DE1225167B (de) | 1965-04-07 | 1966-09-22 | Huels Chemische Werke Ag | Verfahren zur Herstellung aliphatischer, aromatischer oder gemischt aliphatisch-aromatischer Sulfone |
| JPS5498337A (en) | 1978-01-06 | 1979-08-03 | Dai Ichi Seiyaku Co Ltd | Anticarcinogenic and/or antimetastatic agent |
| JPS61129126A (ja) * | 1984-11-28 | 1986-06-17 | Kureha Chem Ind Co Ltd | 抗腫瘍剤 |
| DE4039734A1 (de) | 1990-12-13 | 1992-06-17 | Basf Ag | Substituierte 2-aminothiophene enthaltende herbizide mittel |
| GB9310700D0 (en) | 1993-05-24 | 1993-07-07 | Zeneca Ltd | Novel composition |
| JP3074640B2 (ja) | 1995-12-22 | 2000-08-07 | インターナショナル・ビジネス・マシーンズ・コーポレ−ション | 液晶表示装置の駆動方法 |
| GB9614718D0 (en) | 1996-07-12 | 1996-09-04 | Bayer Ag | 3-ureido-pyridofurans and -pyridothiophenes |
| EP1014962A4 (en) * | 1997-06-26 | 2007-06-27 | Lilly Co Eli | ANTITHROMBOTIC AGENTS |
| WO1999046267A1 (en) | 1998-03-12 | 1999-09-16 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (ptpases) |
| WO2000014090A1 (en) | 1998-09-02 | 2000-03-16 | Novo Nordisk A/S | 4,5,6,7-tetrahydro-thieno[2,3-c]pyridine derivatives |
| JP4548882B2 (ja) * | 1999-11-30 | 2010-09-22 | 興和創薬株式会社 | ４，５，６，７−テトラヒドロチエノ〔２，３−ｃ〕ピリジン化合物 |
| US6414013B1 (en) * | 2000-06-19 | 2002-07-02 | Pharmacia & Upjohn S.P.A. | Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention |
| GB0114185D0 (en) | 2001-06-12 | 2001-08-01 | Protherics Molecular Design Lt | Compounds |
| WO2002092076A1 (en) | 2001-05-16 | 2002-11-21 | Cytovia, Inc. | Substituted coumarins and quinolines as caspases activators |
| WO2003084947A1 (en) | 2002-04-09 | 2003-10-16 | Axxima Pharmaceuticals Ag | 4,5,6,7-tretrahydrobenzo[b] thiophene derivatives and methods for medical intervention against mycrobacterial infections |
| US20040171603A1 (en) | 2001-05-18 | 2004-09-02 | Janos Pato | Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor |
| US20030232994A1 (en) * | 2001-10-04 | 2003-12-18 | Shao-Po Lu | Bicyclic thiophene derivatives and combinatorial libraries thereof |
| NZ535959A (en) | 2002-03-27 | 2006-05-26 | Altana Pharma Ag | Novel alkoxypyridine-derivatives as selective inhibitors of inducible nitric oxidase synthase NOS |
| JP4103425B2 (ja) | 2002-03-28 | 2008-06-18 | セイコーエプソン株式会社 | 電気光学装置、電子機器及び投射型表示装置 |
| US7227540B2 (en) * | 2002-04-25 | 2007-06-05 | Fujifilm Corporation | Image display unit and method of manufacturing the same |
| US7012100B1 (en) | 2002-06-04 | 2006-03-14 | Avolix Pharmaceuticals, Inc. | Cell migration inhibiting compositions and methods and compositions for treating cancer |
| CA2498399A1 (en) | 2002-09-12 | 2004-03-25 | Merck & Co., Inc. | Method of treating diabetes and related conditions |
| DE60325985D1 (de) * | 2002-09-12 | 2009-03-12 | Merck & Co Inc | Substituierte bizyklische thiophen-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren |
| TW200503994A (en) | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
| IL154306A0 (en) * | 2003-02-05 | 2003-09-17 | Rimonyx Pharmaceuticals Ltd | Pharmaceutical compositions comprising thieno [2,3-c] pyridine derivatives and use thereof |
| US7138529B2 (en) | 2003-04-16 | 2006-11-21 | Hoffmann-La Roche Inc. | Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists |
| EP1670804A2 (en) | 2003-09-10 | 2006-06-21 | GPC Biotech AG | Heterobicyclic compounds as pharmaceutically active agents |
| EA200600607A1 (ru) | 2003-10-01 | 2006-10-27 | Алтана Фарма Аг | Производные имидазопиридина в качестве ингибиторов индуцируемой no-синтазы |
| US20050085531A1 (en) | 2003-10-03 | 2005-04-21 | Hodge Carl N. | Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| GB0324653D0 (en) | 2003-10-22 | 2003-11-26 | Syngenta Participations Ag | Fungicides |
| US20050250794A1 (en) | 2003-12-19 | 2005-11-10 | Andrew Napper | Methods of treating a disorder |
| US7745630B2 (en) | 2003-12-22 | 2010-06-29 | Justin Stephen Bryans | Triazolyl piperidine arginine vasopressin receptor modulators |
| ES2309765T3 (es) | 2004-05-28 | 2008-12-16 | 4Sc Ag | Tetrahidropiridotiofenos. |
| WO2005118592A1 (en) * | 2004-06-04 | 2005-12-15 | Altana Pharma Ag | Tetrahydropyridothiophenes for use in the treatment of cancer |
| US7714134B2 (en) | 2004-06-11 | 2010-05-11 | 4Sc Ag | Compounds and use of tetrahydropyridothiophenes |
| SE0401970D0 (sv) | 2004-08-02 | 2004-08-02 | Astrazeneca Ab | Novel compounds |
| EP1851229A1 (en) | 2005-02-09 | 2007-11-07 | Nycomed GmbH | Tetrahydropyridothiophenes for the treatment of proliferative diseases such as cancer |
| AU2006212179A1 (en) | 2005-02-11 | 2006-08-17 | 4Sc Ag | Tetrahydropyridothiophenes as antripoliferative agents for the treatment of cancer |
| US7714136B2 (en) | 2005-05-25 | 2010-05-11 | 4Sc Ag | Tetrahydropyridothiophenes |
| US7763728B2 (en) | 2005-05-25 | 2010-07-27 | 4Sc Ag | Tetrahydropyridothiophenes |
| WO2008020045A1 (en) | 2006-08-16 | 2008-02-21 | 4Sc Ag | Tetrahydrobenzothiophene derivatives |
-
2006
- 2006-05-24 US US11/920,572 patent/US7714136B2/en not_active Expired - Fee Related
- 2006-05-24 CA CA002609003A patent/CA2609003A1/en not_active Abandoned
- 2006-05-24 EP EP06755301A patent/EP1896484A2/en not_active Withdrawn
- 2006-05-24 JP JP2008512845A patent/JP2008542242A/ja active Pending
- 2006-05-24 AU AU2006251167A patent/AU2006251167A1/en not_active Abandoned
- 2006-05-24 WO PCT/EP2006/062613 patent/WO2006125813A2/en not_active Ceased
-
2009
- 2009-03-26 US US12/412,021 patent/US20090258873A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12527790B2 (en) | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof | |
| ES2364328T3 (es) | Compuesto de pirimidina y composición medicinal del mismo. | |
| KR101546693B1 (ko) | 치환된 퀴놀린 화합물 및 그 사용 방법 | |
| WO2023230477A1 (en) | Pyridine checkpoint kinase 1 (chk1) inhibitors and uses thereof | |
| WO2024118564A1 (en) | Checkpoint kinase 1 (chk1) inhibitors and uses thereof | |
| TW200426147A (en) | Quinazolines useful as modulators of ion channels | |
| TW201808888A (zh) | 整合應激途徑之調節劑 | |
| KR20100137551A (ko) | 벤조피란 및 벤족세핀 ｐｉ３ｋ 저해제 화합물 및 이의 사용 방법 | |
| PT2727918T (pt) | Compostos e composições como inibidores de proteína quinase | |
| WO2014164767A1 (en) | Novel compounds and compositions for inhibition of fasn | |
| WO2013189237A1 (zh) | 穿心莲内酯类似物及其治疗的应用 | |
| WO2018210988A1 (en) | Pyrimidine derivatives as pge2 receptor modulators | |
| KR20040004705A (ko) | 카스파제의 활성제 및 아폽토시스의 유도제로서의 치환된3-아릴-5-아릴-[1,2,4]-옥사디아졸과 유사체 및 이의 용도 | |
| CN114748622A (zh) | P38激酶抑制剂降低dux4和下游基因表达以用于治疗fshd | |
| RU2013144571A (ru) | Алинзамещенные хиназолины и способы их применения | |
| JP2008542242A5 (https=) | ||
| JP2021121629A (ja) | Ｓｔａｔ３経路阻害薬およびキナーゼ阻害薬を用いて癌を治療するための方法 | |
| KR20240101555A (ko) | 사이클릭 설폰아미드 리보뉴클레오타이드 환원효소(rnr) 억제제 및 이의 용도 | |
| JP2008534637A5 (https=) | ||
| JP2008529989A5 (https=) | ||
| CN118488945A (zh) | 磺酰胺核糖核苷酸还原酶(rnr)抑制剂及其用途 | |
| CN103172606A (zh) | 具有抗肿瘤活性的香豆素类化合物 | |
| JP2008530053A5 (https=) | ||
| CN113966329B (zh) | 作为pdl1检查点抑制剂的杂环免疫调节剂 | |
| CN104788365B (zh) | 异烟酰胺衍生物、其制备方法及应用 |